Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C

NCT01532908 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped The study was terminated due to funding constraints

Conditions

Hepatitis C Infection

Interventions

BIOLOGICAL: MBL-HCV1
DRUG: Telaprevir (Part 1)
DRUG: Sofosbuvir (Part 2)

Sponsor

MassBiologics